Tailoring dendrimer conjugates for biomedical applications: the impact of altering hydrophobicity
Source abstract
Abstract
Hydrophobicity is known to play a key role in the biological distribution of materials but is often an overlooked parameter when conjugating targeting agents, drugs, and dyes to dendrimers. This review examines the impact of hydrophobic variation in stochastically conjugated dendrimers as well as materials where synthetic methods or approaches to purification provide more controlled samples. Hydrophobic interactions are considered for three general classes: (1) terminal functional group modifications, (2) bioactive small molecules chosen to interact with receptors and proteins as targeting agents and/or drugs, and (3) imaging agents to track biological activity. Impacts on membrane interaction and cellular uptake, biodistribution, interaction with transport proteins, and pharmacokinetics are discussed. The size range of the dendrimers discussed is ~ 1–10 nm.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Dendrimers and Hyperbranched Polymers · RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (51)
Show source-provided references
1. Chen J, van Dongen MA, Merzel RL, Dougherty CA, Orr BG, Kanduluru AK, Low PS, Marsh ENG, Holl MMB (2016) Substrate-triggered exosite binding: synergistic dendrimer/folic acid action for achieving specific, tight-binding to folate binding protein. Biomacromolecules 17(3):922–92710.1021/acs.biomac.5b01586 ↗
2. Dougherty CA, Furgal JC, Van Dongen MA, Goodson T, Banaszak Holl MM, Manono J, DiMaggio S (2014) Isolation and characterization of precise/dye dendrimer ratios. Chem Eur J 20:4638–464510.1002/chem.201304854 ↗
3. Dougherty CA, Vaidyanathan S, Banaszak Holl MM (2015) Fluorophore:dendrimer ratio impacts cellular uptake and fluorescence lifetime. Bioconjug Chem 26:304–31510.1021/bc5005735 ↗
4. Duncan R, Gaspar R (2011) Nanomedicine(s) under the microscope. Mol Pharm 8(6):2101–214110.1021/mp200394t ↗
5. Florence AT, Sakthivel T, Toth I (2000) Oral uptake and translocation of a polylysine dendrimer with a lipid surface. J Control Release 65(1–2):253–25910.1016/S0168-3659(99)00237-0 ↗
6. Haque S, McLeod VM, Jones S, Fung S, Whittaker M, McIntosh M, Pouton C, Owen DJ, Porter CJH, Kaminskas LM (2017) Effect of increased surface hydrophobicity via drug conjugation on the clearance of inhaled PEGylated polylysine dendrimers. Eur J Pharm Biopharm 119:408–41810.1016/j.ejpb.2017.07.005 ↗
7. Janaszewska A, Studzian M, Petersen JF, Ficker M, Paolucci V, Christensen JB, Tomalia DA, Klajnert-Maculewicz B (2017) Modified PAMAM dendrimer with 4-carbomethoxypyrrolidone surface groups-its uptake, efflux, and location in a cell. Colloids Surf B Biointerfaces 159:211–21610.1016/j.colsurfb.2017.07.052 ↗
8. Jevprasesphant R, Penny J, Attwood D, McKeown NB, D'Emanuele A (2003) Engineering of dendrimer surfaces to enhance transepithelial transport and reduce cytotoxicity. Pharm Res 20(10):1543–155010.1023/A:1026166729873 ↗
9. Jevprasesphant R, Penny J, Attwood D, D'Emanuele A (2004) Transport of dendrimer nanocarriers through epithelial cells via the transcellular route. J Control Release 97(2):259–26710.1016/j.jconrel.2004.03.022 ↗
10. Kaminskas LM, Boyd BJ, Porter CJH (2011) Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties. Nanomedicine 6:1063–108410.2217/nnm.11.67 ↗
11. Kaminskas LM, McLeod VM, Ryan GM, Kelly BD, Haynes JM, Williamson M, Thienthong N, Owen DJ, Porter CJH (2014) Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy. J Control Release 183:18–2610.1016/j.jconrel.2014.03.012 ↗
12. Kannan S, Dai H, Navath RS, Balakrishnan B, Jyoti A, Janisse J, Romero R, Kannan RM (2012) Dendrimer-based postnatal therapy for neuroinflammation and cerebral palsy in a rabbit model. Sci Transl Med 4(130):130ra14610.1126/scitranslmed.3003162 ↗
13. Kelkar SS, Reineke TM (2011) Theranostics: combining imaging and therapy. Bioconjug Chem 22(10):1879–190310.1021/bc200151q ↗
14. Kelly CV, Leroueil PR, Orr BG, Holl MMB, Andricioaei I (2008) Poly(amidoamine) dendrimers on lipid bilayers II: effects of bilayer phase and dendrimer termination. J Phys Chem B 112(31):9346–935310.1021/jp8013783 ↗
15. Kitchens KM, Kolhatkar RB, Swaan PW, Eddington ND, Ghandehari H (2006) Transport of poly(amidoamine) dendrimers across Caco-2 cell monolayers: influence of size, charge and fluorescent labeling. Pharm Res 23(12):2818–282610.1007/s11095-006-9122-2 ↗
16. Kojima C, Regino C, Umeda Y, Kobayashi H, Kono K (2010) Influence of dendrimer generation and polyethylene glycol length on the biodistribution of PEGylated dendrimers. Int J Pharm 383(1–2):293–29610.1016/j.ijpharm.2009.09.015 ↗
17. Kono K, Liu MJ, Frechet JMJ (1999) Design of dendritic macromolecules containing folate or methotrexate residues. Bioconjug Chem 10(6):1115–112110.1021/bc990082k ↗
18. Kono K, Akiyama H, Takahashi T, Takagishi T, Harada A (2005) Transfection activity of polyamidoamine dendrimers having hydrophobic amino acid residues in the periphery. Bioconjug Chem 16(1):208–21410.1021/bc049785e ↗
19. Kukowska-Latallo JF, Candido KA, Cao ZY, Nigavekar SS, Majoros IJ, Thomas TP, Balogh LP, Khan MK, Baker JR (2005) Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res 65(12):5317–532410.1158/0008-5472.CAN-04-3921 ↗
20. Larson N, Ghandehari H (2012) Polymeric conjugates for drug delivery. Chem Mater 24(5):840–85310.1021/cm2031569 ↗
21. Lei J, Rosenzweig JM, Mishra MK, Alshehri W, Brancusi F, McLane M, Almalki A, Bahabry R, Arif H, Rozzah R, Alyousif G, Shabi Y, Alhehaily N, Zhong WY, Facciabene A, Kannan S, Kannan RM, Burd I (2017) Maternal dendrimer-based therapy for inflammation-induced preterm birth and perinatal brain injury. Sci Rep 7:610610.1038/s41598-017-06113-2 ↗
22. Liaw K, Gok O, DeRidder LB, Kannan S, Kannan RM (2018) Quantitative assessment of surface functionality effects on microglial uptake and retention of PAMAM dendrimers. J Nanopart Res 20(4):11110.1007/s11051-018-4219-1 ↗
23. Magruder JT, Crawford TC, Lin YA, Zhang F, Grimm JC, Kannan RM, Kannan S, Sciortino CM (2017) Selective localization of a novel dendrimer nanoparticle in myocardial ischemia-reperfusion injury. Ann Thorac Surg 104(3):891–89810.1016/j.athoracsur.2016.12.051 ↗
24. Majoros IJ, Keszler B, Woehler S, Bull T, Baker JR (2003) Acetylation of poly(amidoamine) dendrimers. Macromolecules 36(15):5526–552910.1021/ma021540e ↗
25. Majoros I, Myc A, Thomas T, Mehta CB, Baker JR (2006) PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, conjugation, and functionality. Biomacromolecules 7:572–57910.1021/bm0506142 ↗
26. Mastorakos P, Kambhampati SP, Mishra MK, Wu T, Song E, Hanes J, Kannan RM (2015) Hydroxyl PAMAM dendrimer-based gene vectors for transgene delivery to human retinal pigment epithelial cells. Nanoscale 7(9):3845–385610.1039/C4NR04284K ↗
27. Menjoge AR, Kannan RM, Tomalia DA (2010) Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. Drug Discov Today 15(5–6):171–18510.1016/j.drudis.2010.01.009 ↗
28. Merzel RL, Frey C, Chen J, Garn R, van Dongen MA, Dougherty CA, Kanduluru AK, Low PS, Marsh ENG, Banaszak Holl MM (2017) Conjugation dependent interaction of folic acid with folate binding protein. Bioconjug Chem 28:2350–236010.1021/acs.bioconjchem.7b00373 ↗
29. Merzel RL, Orr BG, Banaszak Holl MM (2018) Distributions: the importance of the chemist's view for biological materials. Biomacromolecules 19:1469–148410.1021/acs.biomac.8b00375 ↗
30. Mishra MK, Beaty CA, Lesniak WG, Kambhampati SR, Zhang F, Wilson MA, Blue ME, Troncoso JC, Kannan S, Johnston MV, Baumgartner WA, Kannan RM (2014) Dendrimer brain uptake and targeted therapy for brain injury in a large animal model of hypothermic circulatory arrest. ACS Nano 8(3):2134–214710.1021/nn404872e ↗
31. Mullen DG, Banaszak Holl MM (2011) Heterogeneous ligand-nanoparticle distributions: a major obstacle to scientific understanding and commercial translation. Acc Chem Res 44:1135–114510.1021/ar1001389 ↗
32. Mullen DG, Fang M, Desai A, Baker JR, Orr BG, Banaszak Holl MM (2010) A quantitative assessment of nanoparticle ligand distributions: implications for targeted drug and imaging delivery in dendrimer conjugates. ACS Nano 4:657–67010.1021/nn900999c ↗
33. Patri AK, Majoros IJ, Baker JR (2002) Dendritic polymer macromolecular carriers for drug delivery. Curr Opin Chem Biol 6(4):466–47110.1016/S1367-5931(02)00347-2 ↗
34. Patri AK, Kukowska-Latallo JF, Baker JR (2005) Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. Adv Drug Deliv Rev 57(15):2203–221410.1016/j.addr.2005.09.014 ↗
35. Quintana A, Raczka E, Piehler L, Lee I, Myc A, Majoros I, Patri AK, Thomas T, Mule J, Baker JR (2002) Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm Res 19(9):1310–131610.1023/A:1020398624602 ↗
36. Sakthivel T, Toth I, Florence AT (1998) Synthesis and physicochemical properties of lipophilic polyamide dendrimers. Pharm Res 15(5):776–78210.1023/A:1011935406664 ↗
37. Santos JL, Oliveira H, Pandita D, Rodrigues J, Pego AP, Granja PL, Tomas H (2010) Functionalization of poly(amidoamine) dendrimers with hydrophobic chains for improved gene delivery in mesenchymal stem cells. J Control Release 144(1):55–6410.1016/j.jconrel.2010.01.034 ↗
38. Shah DS, Sakthivel T, Toth I, Florence AT, Wilderspin AF (2000) DNA transfection and transfected cell viability using amphipathic asymmetric dendrimers. Int J Pharm 208(1–2):41–4810.1016/S0378-5173(00)00534-2 ↗
39. Shi XG, Wang SH, Meshinchi S, Van Antwerp ME, Bi XD, Lee IH, Baker JR (2007) Dendrimer-entrapped gold nanoparticles as a platform for cancer-cell targeting and imaging. Small 3(7):1245–125210.1002/smll.200700054 ↗
40. Singh P, Gupta U, Asthana A, Jain NK (2008) Folate and folate-PEG-PAMAM dendrimers: synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing mice. Bioconjug Chem 19(11):2239–225210.1021/bc800125u ↗
41. Tomalia DA, Naylor AM, Goddard WA (1990) Starburst dendrimers - molecular-level control of size, shape, surface-chemistry, topology, and flexibility from atoms to macroscopic matter. Angew Chem Int Ed Engl 29(2):138–17510.1002/anie.199001381 ↗
42. Vaidyanathan S, Kaushik M, Dougherty C, Rattan R, Goonewardena SN, Banaszak Holl MM, Monano J, DiMaggieo S (2016) Increase in dye:dendrimer ratio decreases cellular uptake of neutral dendrimers in RAW cells. ACS Biomater Sci Eng 2(9):1540–154510.1021/acsbiomaterials.6b00308 ↗
43. van Dongen M, Dougherty CA, Banaszak Holl MM (2014) Multivalent polymers for drug delivery and imaging: the challenges of conjugation. Biomacromolecules 15:3215–323410.1021/bm500921q ↗
44. Wu LP, Ficker M, Christensen JB, Trohopoulos PN, Moghimi SM (2015) Dendrimers in medicine: therapeutic concepts and pharmaceutical challenges. Bioconjug Chem 26(7):1198–121110.1021/acs.bioconjchem.5b00031 ↗
45. Xiao TY, Cao XY, Hou WX, Peng C, Qiu JR, Shi XY (2015) Poly(amidoamine) dendrimers modified with 1,2-Epoxyhexane or 1,2-Epoxydodecane for enhanced gene delivery applications. J Nanosci Nanotechnol 15(12):10134–1014010.1166/jnn.2015.11693 ↗
46. Yoo H, Juliano RL (2000) Enhanced delivery of antisense oligonucleotides with fluorophore-conjugated PAMAM dendrimers. Nucleic Acids Res 28(21):4225–423110.1093/nar/28.21.4225 ↗
47. Yuba E, Nakajima Y, Tsukamoto K, Iwashita S, Kojima C, Harada A, Kono K (2012) Effect of unsaturated alkyl chains on transfection activity of poly(amidoamine) dendron-bearing lipids. J Control Release 160(3):552–56010.1016/j.jconrel.2012.04.002 ↗
48. Zhang F, Nance E, Zhang Z, Jasty V, Kambhampati SP, Mishra MK, Burd I, Romero R, Kannan S, Kannan RM (2016) Surface functionality affects the biodistribution and microglia-targeting of intra-amniotically delivered dendrimers. J Control Release 237:61–7010.1016/j.jconrel.2016.06.046 ↗
49. Zhang F, Magruder JT, Lin YA, Crawford TC, Grimm JC, Sciortino CM, Wilson MA, Blue ME, Kannan S, Johnston MV, Baumgartner WA, Kannan RM (2017) Generation-6 hydroxyl PAMAM dendrimers improve CNS penetration from intravenous administration in a large animal brain injury model. J Control Release 249:173–18210.1016/j.jconrel.2017.01.032 ↗
50. Zheng Y, Fu F, Zhang M, Shen M, Zhu M, Shi X (2014) Multifunctional dendrimers modified with alpha-tocopheryl succinate for targeted cancer therapy. Med Chem Commun 5:879–88510.1039/C3MD00324H ↗
51. Zhu J, Zhao L, Cheng Y, Xiong Z, Tang Y, Shen M, Zhao J, Shi X (2015) Radionuclide 131I-labeled multifunctional dendrimers for targeted SPECT imaging and radiotherapy of tumors. Nanoscale 7:18169–1817810.1039/C5NR05585G ↗